A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Objective: Colorectal cancer (CRC) is the second leading cause of cancer death in the United States. Cyclooxygenase-2 (COX-2) overexpression is associated with increased tumor invasiveness and proliferation in CRC, and COX-2 inhibition has demonstrated chemopreventive activity. This study investigated the addition of celecoxib, a selective COX-2 inhibitor, to the irinotecan, 5-fluorouracil, and leucovorin (IFL) regimen for patients with previously untreated metastatic CRC. Patients and Methods: Forty-seven patients enrolled in this single-arm phase II study received celecoxib at 400 mg orally twice daily in combination with weekly irinotecan (125 mg/m 2), 5-fluorouracil (500 mg/m 2), and leucovorin (20 mg/m 2) for 4 weeks every 6 weeks. The primary endpoint was response rate (RR) as measured by Response Evaluation Criteria in Solid Tumors. The protocol was amended midway to additionally exclude patients with Eastern Cooperative Oncology Group performance status 2 and require all patients with specific cardiovascular risk factors to take daily aspirin (81 mg). Results: The objective RR was 31.9% (95% confidence interval [CI], 19%-47%). Median progression-free survival was 8.7 months (95% CI, 5.8-10.6), and the median overall survival was 19.7 months (95% CI, 15.4-22.8). All cardiac events were observed before protocol modification. The median overall survival before and after protocol modification was 11.4 versus 24.2 months, respectively (P<0.0001); tumor RR and progression-free survival were not statistically different before or after protocol modification. The trial was halted after an interim analysis demonstrated that the primary endpoint would not be met. Conclusions: Celecoxib plus IFL chemotherapy for patients with metastatic CRC is tolerable, but does not appear to increase the efficacy of IFL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although several prior clinical trials testing SRC or COX2 inhibitors in patients with CRC have failed to show meaningful clinical activity48–53”
From A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors (2023) · cites this paper as [51]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citationRandomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431
Self-citation
Research works printed but not linked: 23
- Siegel, 2017, Colorectal cancer statistics, 2017, CA Cancer J Clin, 67, 177, 10.3322/caac.21395 · DOI · Paper page
- Piedbois, 1998, Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer, J Clin Oncol, 16, 301, 10.1200/JCO.1998.16.1.301 · DOI · Paper page
- Elez, 2015, First-line treatment of metastatic colorectal cancer: interpreting FIRE-3, PEAK, and CALGB/SWOG 80405, Curr Treat Options Oncol, 16, 52, 10.1007/s11864-015-0369-x · DOI
- Saltz, 2000, Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group, N Engl J Med, 343, 905, 10.1056/NEJM200009283431302 · DOI · Paper page
- Kohne, 2010, How to integrate molecular targeted agents in the continuum of care, Ann Oncol, 21, vii134, 10.1093/annonc/mdq374 · DOI
- Sheehan, 1999, The relationship between cyclooxygenase-2 expression and colorectal cancer, JAMA, 282, 1254, 10.1001/jama.282.13.1254 · DOI · Paper page
- Baron, 2006, A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas, Gastroenterology, 131, 1674, 10.1053/j.gastro.2006.08.079 · DOI · Paper page
- Thompson, 2016, Celecoxib for the prevention of colorectal adenomas: results of a suspended randomized controlled trial, J Natl Cancer Inst, 108, 12, 10.1093/jnci/djw151 · DOI
- Li, 2015, Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis, Gut, 64, 1419, 10.1136/gutjnl-2014-308260 · DOI
- Blanke, 2005, A phase I study of 5-fluorouracil, leucovorin, and celecoxib in patients with incurable colorectal cancer, Prostaglandins Other Lipid Mediat, 75, 169, 10.1016/j.prostaglandins.2004.10.004 · doi:10.1016/j.prostaglandins.2004.10.004
- Sheng, 1997, Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2, J Clin Invest, 99, 2254, 10.1172/JCI119400 · DOI · Paper page
- Maier, 2004, Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells, Biochem Pharmacol, 67, 1469, 10.1016/j.bcp.2003.12.014 · DOI · Paper page
- Irie, 2007, Synergistic antitumor effects of celecoxib with 5-fluorouracil depend on IFN-gamma, Int J Cancer, 121, 878, 10.1002/ijc.22720 · DOI
- Masferrer, 2000, Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors, Cancer Res, 60, 1306
- Solomon, 2005, Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention, N Engl J Med, 352, 1071, 10.1056/NEJMoa050405 · DOI · Paper page
- Solomon, 2006, Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas, Circulation, 114, 1028, 10.1161/CIRCULATIONAHA.106.636746 · DOI · Paper page
- Goldberg, 2004, A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer, J Clin Oncol, 22, 23, 10.1200/JCO.2004.09.046 · DOI · Paper page
- Andre, 2007, Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study, Ann Oncol, 18, 77, 10.1093/annonc/mdl336 · DOI · Paper page
- Maiello, 2006, FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell’Italia Meridionale (GOIM), Ann Oncol, 17, vii55, 10.1093/annonc/mdl952 · DOI · Paper page
- Kohne, 2008, Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015, Ann Oncol, 19, 920, 10.1093/annonc/mdm544 · DOI · Paper page
- Fuchs, 2007, Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study, J Clin Oncol, 25, 4779, 10.1200/JCO.2007.11.3357 · DOI · Paper page
- Bertagnolli, 2006, Celecoxib for the prevention of sporadic colorectal adenomas, N Engl J Med, 355, 873, 10.1056/NEJMoa061355 · DOI · Paper page
- Bains, 2016, Aspirin as secondary prevention in patients with colorectal cancer: an unselected population-based study, J Clin Oncol, 34, 2501, 10.1200/JCO.2015.65.3519 · DOI
Cited by
Steps in metastasis: an updated review
Majidpoor, J., & Mortezaee, K. (2021) · Medical Oncology · doi:10.1007/s12032-020-01447-w · Cited by 264
Drug repurposing to overcome resistance to various therapies for colorectal cancer
Fong, W., & To, K. K. W. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03134-0 · Cited by 81
Ruiz-Saenz, A., Atreya, C. E., Wang, C., Pan, B., Dreyer, C. A., Brunen, D., Prahallad, A., Muñoz, D. P., Ramms, D. J., Burghi, V., et al. (2023) · Nature Cancer · doi:10.1038/s43018-022-00508-5 · Cited by 39
Metadata
- Authors
- Chen, E. Y., Blanke, C. D., Haller, D. G., Benson, A. B., Dragovich, T., Lenz, H.-J., Robles, C., Li, H., Mori, M., Mattek, N., Sanborn, R. E., & Lopez, C. D.
- Affiliations
- Knight Cancer Institute, Oregon Health and Sciences University
- Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
- Department of Medical Oncology, Northwestern University, Chicago, IL
- Banner MD Anderson Cancer Center, Gilbert, AZ
- Division of Medical Oncology, Keck School of Medicine, University of Southern California, Los Angeles, CA
- Cape Medical Oncology, Cape Girardeau, MO
- Lerner Research Institute, Cleveland Clinic, Cleveland, OH
- Earle A. Chiles Research Institute, Providence Cancer Center, Portland, OR
- Venue
- American Journal of Clinical Oncology
- Published
- 2018-12
- Volume
- 41
- Issue
- 12
- Pages
- 1193-1198
- ISSN
- 0277-3732
- Cited by
- 23
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. https://app.cochat.ai/papers/10.1097/coc.0000000000000465
- The paper
- Chen, E. Y., Blanke, C. D., Haller, D. G., Benson, A. B., Dragovich, T., Lenz, H.-J., Robles, C., Li, H., Mori, M., Mattek, N., Sanborn, R. E., & Lopez, C. D. (2018). A Phase II Study of Celecoxib With Irinotecan, 5-Fluorouracil, and Leucovorin in Patients With Previously Untreated Advanced or Metastatic Colorectal Cancer. American Journal of Clinical Oncology. https://doi.org/10.1097/coc.0000000000000465
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.